SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about investor meeting

22 Feb 2023 Evaluate

Aurobindo Pharma has informed that it enclosed details of investor meeting on 23-02-2023. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1621.70 61.65 (3.95%)
03-Jul-2026 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.00
Dr. Reddys Labs. 1373.15
Cipla 1456.65
Zydus Lifesciences 1135.70
Lupin 2467.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: